CDC Emerging Infectious Diseases: R292K Substitution and Drug Susceptibility of Influenza A(H7N9) Viruses

Volume 19, Number 9—September 2013

Dispatch

Abstract

Neuraminidase inhibitors are the only licensed antiviral medications available to treat avian influenza A(H7N9) virus infections in humans. According to a neuraminidase inhibition assay, an R292K substitution reduced antiviral efficacy of inhibitors, especially oseltamivir, and decreased viral fitness in cell culture. Monitoring emergence of R292K-carrying viruses using a pH-modified neuraminidase inhibition assay should be considered.

Katrina Sleeman¹, Zhu Guo¹, John Barnes, Michael Shaw, James Stevens, and Larisa V. Gubareva 

Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA

http://wwwnc.cdc.gov/eid/article/19/9/13-0724_article.htm?s_cid=eid-gDev-email